Hims & Hers Buys Lab to Expand Into At-Home Blood Testing

Bloomberg
02-19
  • Hims shares have soared on demand for copycat obesity drugs

  • Purchase of Sigmund brings test kits for hormones, cholesterol

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the acquisition of a home blood-testing company.

The telehealth provider purchased Sigmund NJ LLC, which uses a US-approved device for home testing of hormones, cholesterol and other markers of health, according to a statement on Wednesday. New Jersey-based Sigmund markets its services as Trybe Labs. Terms of the deal weren’t disclosed.

Hundreds of thousands of Americans have turned to Hims and other telehealth companies for copies of weight-loss drugs after struggling to access brand-name versions made by Novo Nordisk A/S and Eli Lilly & Co. Hims ran a high-profile Super Bowl ad on Feb. 9 touting its compounded drugs, while criticizing the US health-care system.

Compounders are permitted to make copies of brand-name drugs during shortages. The company’s shares have risen sixfold over the past year through Tuesday’s close amid demand for its compounded drugs. The stock gained as much as 17% in morning trading.

Using the home kits will allow Hims to support more comprehensive patient testing and broaden its offering of personalized treatments, supplements and medications, according to the statement.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10